Angiogenesis as a therapeutic target

@article{Ferrara2005AngiogenesisAA,
  title={Angiogenesis as a therapeutic target},
  author={Napoleone Ferrara and Robert S. Kerbel},
  journal={Nature},
  year={2005},
  volume={438},
  pages={967-974}
}
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of… 

Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.

Antiangiogenesis to treat cancer and intraocular neovascular disorders

Progress in targeting one of the major regulators of angiogenesis, VEGF-A, is focused on, and potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments are discussed.

Antiangiogenic Therapy for Cancer: An Update

Clinical progress in targeting one of the major regulators of angiogenesis, vascular endothelial growth factor-A, is focused on and some recent advances in the elucidation of potential cellular and molecular mechanisms underlying refractoriness or resistance to antiangiogenic therapies are discussed.

Targeting VEGF-A to treat cancer and age-related macular degeneration.

This review summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule and describes the neovascular form of age-related macular degeneration.

Emerging technologies for enabling proangiogenic therapy

Various protein engineering strategies to develop stabilized proangiogenic proteins and several biomaterial technologies used to amplify the angiogenic outcome by delivering biologically active growth factors in a sustained manner are discussed.

Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor

This chapter summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule, which resulted in a therapeutic benefit in a variety of models of cancer and intraocular neovascular syndromes.

VEGF inhibition: insights from preclinical and clinical studies

This review examines the various mouse tumor models in which VEGF inhibitors have been tested and the lessons learned from these studies.

Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?

The biological mechanisms which underlie the role of angiogenesis in breast cancer carcinogenesis are described, its contribution to the metastatic process is depicted and the immunologic role of VEGF deserves to be further explored.

Hypoxia, angiogenesis, and colorectal cancer

The induction of angiogenesis is a nearly universal feature of solid malignancies, and therapeutic strategies that specifically inhibit this process have now entered the clinical arena. Colorectal
...

References

SHOWING 1-10 OF 111 REFERENCES

Clinical applications of angiogenic growth factors and their inhibitors

Inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes.

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

VEGF and the quest for tumour angiogenesis factors

  • N. Ferrara
  • Medicine, Biology
    Nature Reviews Cancer
  • 2002
The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be

Clinical translation of angiogenesis inhibitors

Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply, and clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.

Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions

Preliminary results of the clinical studies suggest that single-agent antiangiogenic therapy is poorly active in advanced tumors.

The biology of VEGF and its receptors

Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumour angiogenesis and that blockingAngiogenesis is an effective strategy to treat human cancer.

Angiogenesis: where do we stand now?

Some of the current understanding of the regulation of blood vessel growth in mature adult tissues and the various therapeutic applications of this knowledge are examined.

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.

An overview of experimental and clinical studies of combined therapy with antiangiogenic agents is presented and the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclinical andclinical studies using these agents are highlighted.

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  • R. Jain
  • Biology, Medicine
    Science
  • 2005
Emerging evidence supporting an alternative hypothesis is reviewed—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery.
...